Deep brain stimulation for treatment-resistant mental disorders
Official title: Efficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders: a Multi-center, Single Arm, Prospective, Open-label, Extendable Study
Run by Shanghai Mental Health Center · NCT06112067 · Data updated 2026-11-12
This study is testing a new brain stimulation treatment for people with severe mental disorders like OCD and schizophrenia to see if it can help them feel better.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 18 (estimated) |
| Sponsor | Shanghai Mental Health Center Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | October 16, 2023 |
| Main results expected | November 2026 |
| Study ends | December 2026 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT06112067 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-65 with treatment-refractory obsessive-compulsive disorder or schizophrenia who have not responded to multiple medications and therapies.
✕Probably not a fit
Patients with non-treatment refractory mental disorders or those who do not meet the specific inclusion criteria will likely not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the efficacy and safety of combo-stim deep brain stimulation (DBS) for patients with treatment-refractory mental disorders, including obsessive-compulsive disorder and schizophrenia. A total of 18 subjects will undergo neurosurgical implantation of DBS in specific brain regions, with stimulation parameters adjusted after a short recovery period. The effectiveness of the treatment will be assessed using various clinical scales over an 8-24 week period, while safety will be monitored through adverse event reporting and clinical evaluations.
Why it matters
Potential benefit: If successful, this treatment could provide significant relief for patients suffering from severe mental disorders that have not responded to conventional therapies.
How similar studies have gone: Other studies have explored deep brain stimulation for mental disorders, showing promising results, but this specific combination approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Treatment refractory obsessive-compulsive disorder: 1. Aged 18\~65 when signing informed consent, outpatient or inpatient, male or female. 2. Fits DSM-5 obsessive-compulsive disorder criteria. 3. Fits treatment refractory obsessive-compulsive disorder criteria (both i and ii): i.Treated with at least 3 kinds of serotonin reuptake inhibitors (SSRIs) with at least 2 kinds of 2nd generation antipsychotic medication as enhancement, enough dosage and enough course of treatment, and still no effect or intolerant. ii.While using enough dosage of SSRIs, treated with more than 8\~12 times of Cognitive Behavior Therapy (CBT) or CBT-intolerant. d)Y-BOCS score ≥ 25 in screening period and baseline. e)CGI-S score ≥ 4 in screening period and baseline. f)Patient and guardian agree to DBS implant and sign informed consent after fully understood research aims, contents, anticipated treatments and risks. 2. Treatment refractory schizophrenia: 1. Aged 18\~65 when signing informed consent, outpatient or inpatient, male or female. 2. Fits DSM-5 schizophrenia criteria. 3. Course of disorder ≥ 5 years. 4. Fits treatment refractory schizophrenia criteria, one of the conditions below: i.Treated with more than 2 different anti-psychotic medications (clozapine excluded), enough dosage (equivalent dosage as chlorpromazine ≥ 600mg/day), enough course of treatment (≥ 12 weeks), no effect or intolerant. ii.Treated with enough dosage of clozapine (≥ 300mg/day or blood medication concentration ≥ 350ng/ml, enough course of treatment (≥ 12 weeks), no effect or intolerant. e)PANSS score ≥ 70 in screening period and baseline, and at least 1 item from 5 items (P1, P2, P3, P5, P6) of PANSS positive symptom scale ≥ 4; or at least 3 items from PANSS negative symptom scale (N1\~N7) ≥ 4, or at least 2 items ≥ 5. f)CGI-S ≥ 4 in screening period and baseline. g)GAF ≤ 60 in screening period and baseline. h)Patient and guardian agree to DBS implant and sign informed consent after fully understood research aims, contents, anticipated treatments and risks. 3. Treatment refractory bipolar with depression: 1. Aged 18\~65 when signing informed consent, outpatient or inpatient, male or female. 2. Fits DSM-5 bipolar I or bipolar II criteria, currently with depression episode. 3. Course of disorder ≥ 2 years. 4. Fits treatment refractory bipolar with depression criteria (treated with two different kinds of treatment below, enough dosage and enough course of treatment ≥ 8 weeks, and cannot acquire symptom cure for 8 consecutive weeks, either i or ii): i.Used at least two medications (alone) among Olanzapine (10-20mg/d) + Fluoxetine (20-60mg/d), Quetiapine (200-600mg/d), Lurasidone (40-160mg/d), Lamotrigine (200-400mg/d) ii.Used at least one medication above (alone), and used one of medication above with another medication among Lamotrigine (200-400mg/d), Valproate (1000-2000mg/d) and lithium salt (blood lithium reaches 0.8mmol/L). e)Upon medication treatment, electroconvulsive therapy ≥ 12 times, no effect or failed (such as intolerant). f)Fits severe symptom criteria: i.Depression episode ≥ 12 weeks in screening period. ii.MADRS score ≥ 26 in screening period and baseline. iii.GCI-BP score ≥ 4 in screening period and baseline. iv.YMRS score ≥ 12 in screening period and baseline. g)Patient and guardian agree to DBS implant and sign informed consent after fully understood research aims, contents, anticipated treatments and risks. 4. Treatment refractory anorexia nervosa: 1. Aged 18\~65 when signing informed consent, outpatient or inpatient, male or female. 2. Fits DSM-5 anorexia nervosa criteria, consider both restricting type and binge-eating/purging type. 3. 10 ≤ BMI \< 16 in screening period and baseline. 4. Fits treatment refractory anorexia nervosa criteria (both i, ii, iii and iv): i.Course of disorder ≥ 5 years, severe and sustained anorexia nervosa. ii.With ≥ 3 times repeated inpatient history and bad treatment effect (can't complete treatment or immediate relapse after treatment). iii.Through systemic nutrient treatment, medication (SSRIs and/or anti-psychotics), psychotherapies (such as reinforced CBT, FBT treatment), no effect or intolerant. iv.Worsened instability of clinical treatment, refuse treatment or bad reaction to reinforced treatment, last for more than 1 year, with more than 2 times of involuntary food intake. e)Patient and guardian agree to DBS implant and sign informed consent after fully understood research aims, contents, anticipated treatments and risks. 5. Gambling disorder: 1. Aged 18\~65 when signing informed consent, outpatient or inpatient, male or female. 2. Course of disorder ≥ 2 years. 3. Diagnosed as gambling disorder based on DSM-5, fits medium or severe diagnostic standard (≥ 6 terms) 4. Received systemic treatment (such as medication and social mental intervention) but still has iterative thoughts of impulse or gambling behaviors. 5. Patient and guardian agree to DBS implant and sign informed consent after fully understood research aims, contents, anticipated treatments and risks. 6. Adult autism: 1. Aged 18\~65 when signing informed consent, outpatient or inpatient, male or female. 2. Fits DSM-5 autism spectrum disorder diagnostic standard, and there's severe, life-threatening iterative behaviors, and independently evaluated by two psychiatric doctors. 3. AuBC score ≥ 62 in screening period and baseline. 4. CGI-S score ≥ 4 in screening period and baseline. 5. Course of disorder ≥ 10 years, received systemic behavior intervention or training ( such as critical reaction training, cognitive behavior intervention, language expression training, demonstration method, natural environment training, patriarch training, social skill training, intervention based on story tales, etc. ) but failed, or intolerant. 6. Patient and guardian agree to DBS implant and sign informed consent after fully understood research aims, contents, anticipated treatments and risks. Exclusion Criteria: 1. With mental disorders including physical mental disorders, paranoid personality disorder, delayed mental development etc. 2. Through clinical evaluation by investigators, there exists significant suicide behavior risk. 3. From screening period to baseline, patients who has significant improvement in evaluation scores: 1. Obsessive compulsive disorder: Y-BOCS score decreased (or improved) ≥ 20% 2. Schizophrenia: PANSS score decreased (or improved) ≥ 20% 3. Bipolar with depression: MADRS score decreased (or improved) ≥ 20% 4. Anorexia nervosa: BMI improved ≥ 20% 5. Gambling: through evaluation by investigators, online gambling behavior is significantly improved 6. Adult autism: AuBC score decreased (or improved) ≥ 20%. 4. With severe or unstable cardiovascular, inspiratory, liver, kidney, blood, endocrine, neural system or other system disorders. 5. Has neural system disorders including physical brain disorders, brain trauma, treatment-refractory seizure etc. 6. During screening period or baseline, abnormalities in patient's physical examination, laboratory examination, electrocardiogram examination, imaging examination have significant clinical meaning, and patients who are considered unfit by investigators. 7. Implanted artificial cochlea, pacemaker, similar single-side or double-side products or experienced other physical surgeries within half a year that are considered to have effect on this trial by investigators. 8. DBS implant surgery taboos present and is considered unfit by investigators. 9. Diagnosed as HIV positive. 10. Female in gestation, lactation, or blood HCG / urine gestation test positive. Or patients who can't take effective contraception actions during the trial. Or patients planning to birth or give birth after the trial begins for 3 months. 11. Currently involved or involved in other medication or medical device clinical trials 3 months before the screening period. 12. Other patients who are considered unfit by investigators.
Where it's running
-
Shanghai Mental Health Center
Shanghai, China Recruiting
Study contacts
- Principal investigator: Zhen Wang, MD,PhD — Shanghai Mental Health Center
- Study coordinator: Zhen Wang, MD,PhD
- Email: wangzhen@smhc.org.cn
- Phone: 862164387250
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
See if deep brain stimulation for Parkinson's changes thinking and movement and affects fall risk
This pilot study tests whether deep brain stimulation in people with Parkinson’s changes thinking or movement and whether those changes relate to how often they fall.
-
How aerobic exercise (forced vs voluntary cycling) affects movement, thinking, and brain signals in people with Parkinson’s and deep brain stimulation
This study tests whether forced or voluntary cycling improves movement, thinking, and brain activity in people with Parkinson’s who already have a DBS device.
-
Low-intensity focused ultrasound for movement and seizure disorders
This trial will try low-intensity focused ultrasound (LIFUS) to see if it can safely change brain activity in people with movement disorders or epilepsy.
-
Patterned deep brain stimulation delivered at home for Parkinson's
This study will test whether three types of patterned deep brain stimulation can be used safely and comfortably at home in people with Parkinson's who already have stable bilateral STN or GPi Boston Scientific DBS systems.
-
Blood-based predictors of DBS outcomes for Parkinson's disease
This project will test whether proteins and RNA in blood can predict how people with Parkinson's disease will respond to deep brain stimulation (DBS).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.